Page 16 - Solid Biosciences Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The combined company will focus on the advancement of neuromuscular and cardiac programs for the treatment of Duchenne muscular dystrophy.

Ovid Therapeutics (NASDAQ:OVID – Get Rating) and Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Profitability This table compares Ovid Therapeutics and Ultragenyx Pharmaceutical’s net […]

A number of firms have modified their ratings and price targets on shares of Solid Biosciences (NASDAQ: SLDB) recently: 5/3/2022 – Solid Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Solid Biosciences LLC is a life science company. It focuses on developing therapies […]

Equities analysts predict that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will report earnings of ($0.21) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.23) and the highest estimate coming in at ($0.17). Solid Biosciences […]

Equities research analysts expect that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will post earnings per share of ($0.18) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with estimates ranging from ($0.20) to ($0.17). Solid Biosciences posted earnings of ($0.19) per share during the same quarter […]